Response to: The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury

A response to and comment on The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury, by Haleema Shakur, Ian Roberts, et al.

Detalles Bibliográficos
Autor principal: Simmon, Vincent F
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797007/
https://www.ncbi.nlm.nih.gov/pubmed/19958522
http://dx.doi.org/10.1186/1745-6215-10-110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797007/
https://www.ncbi.nlm.nih.gov/pubmed/19958522
http://dx.doi.org/10.1186/1745-6215-10-110

Ejemplares similares